BioCentury
ARTICLE | Clinical News

Zomig-ZMT zolmitriptan oral 5HT1D receptor agonist regulatory update

February 20, 2001 8:00 AM UTC

The FDA granted marketing approval for a fast-dissolving formulation of Zomig to treat migraine. The formulation, which also is approved in Europe, uses CIMA's DuraSolv drug delivery technology. ...